Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results.
Gespeichert in:
| Autor*in: |
Raffi, François [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2013 |
|---|
| Umfang: |
9 |
|---|
| Übergeordnetes Werk: |
Enthalten in: Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model - Berhane, S. ELSEVIER, 2016, New York, NY |
|---|---|
| Übergeordnetes Werk: |
volume:13 ; year:2013 ; number:11 ; pages:927-935 ; extent:9 |
| Links: |
|---|
| DOI / URN: |
10.1016/S1473-3099(13)70257-3 |
|---|
| Katalog-ID: |
ELV02705943X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV02705943X | ||
| 003 | DE-627 | ||
| 005 | 20230623185234.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 180603s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1473-3099(13)70257-3 |2 doi | |
| 028 | 5 | 2 | |a GBVA2013004000015.pica |
| 035 | |a (DE-627)ELV02705943X | ||
| 035 | |a (ELSEVIER)S1473-3099(13)70257-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | |a 610 | |
| 082 | 0 | 4 | |a 610 |q DE-600 |
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.44 |2 bkl | ||
| 100 | 1 | |a Raffi, François |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
| 264 | 1 | |c 2013 | |
| 300 | |a 9 | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. | ||
| 700 | 1 | |a Jaeger, Hans |4 oth | |
| 700 | 1 | |a Quiros-Roldan, Eugenia |4 oth | |
| 700 | 1 | |a Albrecht, Helmut |4 oth | |
| 700 | 1 | |a Belonosova, Elena |4 oth | |
| 700 | 1 | |a Gatell, Jose M |4 oth | |
| 700 | 1 | |a Baril, Jean-Guy |4 oth | |
| 700 | 1 | |a Domingo, Pere |4 oth | |
| 700 | 1 | |a Brennan, Clare |4 oth | |
| 700 | 1 | |a Almond, Steve |4 oth | |
| 700 | 1 | |a Min, Sherene |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Berhane, S. ELSEVIER |t Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |d 2016 |g New York, NY |w (DE-627)ELV013808834 |
| 773 | 1 | 8 | |g volume:13 |g year:2013 |g number:11 |g pages:927-935 |g extent:9 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1473-3099(13)70257-3 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_11 | ||
| 912 | |a GBV_ILN_26 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a GBV_ILN_70 | ||
| 936 | b | k | |a 44.44 |j Parasitologie |x Medizin |q VZ |
| 951 | |a AR | ||
| 952 | |d 13 |j 2013 |e 11 |h 927-935 |g 9 | ||
| 953 | |2 045F |a 610 | ||
| author_variant |
f r fr |
|---|---|
| matchkey_str |
raffifranoisjaegerhansquirosroldaneugeni:2013----:nealdltgaivrutiealrlervrnniervrlavautwthvifcinpigsuy6ekeutfo |
| hierarchy_sort_str |
2013 |
| bklnumber |
44.44 |
| publishDate |
2013 |
| allfields |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
| spelling |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
| allfields_unstemmed |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
| allfieldsGer |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
| allfieldsSound |
10.1016/S1473-3099(13)70257-3 doi GBVA2013004000015.pica (DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 DE-627 ger DE-627 rakwb eng 610 610 DE-600 610 VZ 610 VZ 44.44 bkl Raffi, François verfasserin aut Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial 2013 9 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. Jaeger, Hans oth Quiros-Roldan, Eugenia oth Albrecht, Helmut oth Belonosova, Elena oth Gatell, Jose M oth Baril, Jean-Guy oth Domingo, Pere oth Brennan, Clare oth Almond, Steve oth Min, Sherene oth Enthalten in Elsevier Berhane, S. ELSEVIER Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model 2016 New York, NY (DE-627)ELV013808834 volume:13 year:2013 number:11 pages:927-935 extent:9 https://doi.org/10.1016/S1473-3099(13)70257-3 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 44.44 Parasitologie Medizin VZ AR 13 2013 11 927-935 9 045F 610 |
| language |
English |
| source |
Enthalten in Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model New York, NY volume:13 year:2013 number:11 pages:927-935 extent:9 |
| sourceStr |
Enthalten in Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model New York, NY volume:13 year:2013 number:11 pages:927-935 extent:9 |
| format_phy_str_mv |
Article |
| bklname |
Parasitologie |
| institution |
findex.gbv.de |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| authorswithroles_txt_mv |
Raffi, François @@aut@@ Jaeger, Hans @@oth@@ Quiros-Roldan, Eugenia @@oth@@ Albrecht, Helmut @@oth@@ Belonosova, Elena @@oth@@ Gatell, Jose M @@oth@@ Baril, Jean-Guy @@oth@@ Domingo, Pere @@oth@@ Brennan, Clare @@oth@@ Almond, Steve @@oth@@ Min, Sherene @@oth@@ |
| publishDateDaySort_date |
2013-01-01T00:00:00Z |
| hierarchy_top_id |
ELV013808834 |
| dewey-sort |
3610 |
| id |
ELV02705943X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV02705943X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623185234.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1473-3099(13)70257-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013004000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV02705943X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-3099(13)70257-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Raffi, François</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jaeger, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quiros-Roldan, Eugenia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albrecht, Helmut</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Belonosova, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gatell, Jose M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baril, Jean-Guy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Domingo, Pere</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brennan, Clare</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Almond, Steve</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Min, Sherene</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Berhane, S. ELSEVIER</subfield><subfield code="t">Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model</subfield><subfield code="d">2016</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV013808834</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:927-935</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1473-3099(13)70257-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2013</subfield><subfield code="e">11</subfield><subfield code="h">927-935</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| author |
Raffi, François |
| spellingShingle |
Raffi, François ddc 610 bkl 44.44 Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
| authorStr |
Raffi, François |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV013808834 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 610 DE-600 610 VZ 44.44 bkl Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
| topic |
ddc 610 bkl 44.44 |
| topic_unstemmed |
ddc 610 bkl 44.44 |
| topic_browse |
ddc 610 bkl 44.44 |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
h j hj e q r eqr h a ha e b eb j m g jm jmg j g b jgb p d pd c b cb s a sa s m sm |
| hierarchy_parent_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| hierarchy_parent_id |
ELV013808834 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV013808834 |
| title |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
| ctrlnum |
(DE-627)ELV02705943X (ELSEVIER)S1473-3099(13)70257-3 |
| title_full |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
| author_sort |
Raffi, François |
| journal |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| journalStr |
Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2013 |
| contenttype_str_mv |
zzz |
| container_start_page |
927 |
| author_browse |
Raffi, François |
| container_volume |
13 |
| physical |
9 |
| class |
610 610 DE-600 610 VZ 44.44 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Raffi, François |
| doi_str_mv |
10.1016/S1473-3099(13)70257-3 |
| dewey-full |
610 |
| title_sort |
once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with hiv-1 infection (spring-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
| title_auth |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
| abstract |
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. |
| abstractGer |
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. |
| abstract_unstemmed |
In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results. |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U SSG-OLC-PHA GBV_ILN_11 GBV_ILN_26 GBV_ILN_40 GBV_ILN_70 |
| container_issue |
11 |
| title_short |
Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial |
| url |
https://doi.org/10.1016/S1473-3099(13)70257-3 |
| remote_bool |
true |
| author2 |
Jaeger, Hans Quiros-Roldan, Eugenia Albrecht, Helmut Belonosova, Elena Gatell, Jose M Baril, Jean-Guy Domingo, Pere Brennan, Clare Almond, Steve Min, Sherene |
| author2Str |
Jaeger, Hans Quiros-Roldan, Eugenia Albrecht, Helmut Belonosova, Elena Gatell, Jose M Baril, Jean-Guy Domingo, Pere Brennan, Clare Almond, Steve Min, Sherene |
| ppnlink |
ELV013808834 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth oth oth oth oth oth oth oth |
| doi_str |
10.1016/S1473-3099(13)70257-3 |
| up_date |
2024-07-06T20:58:45.514Z |
| _version_ |
1803864795265368064 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV02705943X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230623185234.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">180603s2013 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/S1473-3099(13)70257-3</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">GBVA2013004000015.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV02705943X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S1473-3099(13)70257-3</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2=" "><subfield code="a">610</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">DE-600</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.44</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Raffi, François</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2013</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">9</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In the primary analysis of SPRING-2 at week 48, dolutegravir showed non-inferior efficacy to and similar tolerability to raltegravir in adults infected with HIV-1 and naive for antiretroviral treatment. We present the 96 week results.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Jaeger, Hans</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Quiros-Roldan, Eugenia</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Albrecht, Helmut</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Belonosova, Elena</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Gatell, Jose M</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Baril, Jean-Guy</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Domingo, Pere</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Brennan, Clare</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Almond, Steve</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Min, Sherene</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Berhane, S. ELSEVIER</subfield><subfield code="t">Identification of Advanced Fibrosis in Hepatitis C Patients following Sustained Virologic Response: A New Predictive Model</subfield><subfield code="d">2016</subfield><subfield code="g">New York, NY</subfield><subfield code="w">(DE-627)ELV013808834</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:13</subfield><subfield code="g">year:2013</subfield><subfield code="g">number:11</subfield><subfield code="g">pages:927-935</subfield><subfield code="g">extent:9</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/S1473-3099(13)70257-3</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SSG-OLC-PHA</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_11</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_26</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_70</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.44</subfield><subfield code="j">Parasitologie</subfield><subfield code="x">Medizin</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">13</subfield><subfield code="j">2013</subfield><subfield code="e">11</subfield><subfield code="h">927-935</subfield><subfield code="g">9</subfield></datafield><datafield tag="953" ind1=" " ind2=" "><subfield code="2">045F</subfield><subfield code="a">610</subfield></datafield></record></collection>
|
| score |
7.399912 |